Open-Label Lead-In Study of MDMA-Assisted Therapy for PTSD: 29th Participant Completes Treatment

Twenty-nine participants have completed treatment in our Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at planned Phase 3 sites across the United States and Canada. The purpose of this study is to provide the final training and provide supervision for our co-therapy teams as they each work with one subject with PTSD using the same treatment approach to be used in Phase 3. Study sites are now enrolling and 8 sites are fully enrolled. The study is expected to be completed in mid 2019.